130403-21-3

Upstream product

• 1074-82-4 potassium phtalimide 
• 632-46-2 2,6-dimethylbenzoic acid 
• 6781-98-2 2,6-dimethyl-1-chlorobenzene 
• 136918-14-4 phthalimide 
• 62285-58-9 2,6-dimethylbenzyl alcohol 
• 5402-60-8 2,6-dimethylbenzyl chloride 

Downstream Products

• 1055039-07-0 Acetic acid 3-{(1S,2S)-1-benzyl-3-[(R)-4-(2,6-dimethyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 
• 226997-95-1 (R)-N-(2,6-dimethylbenzyl)-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide 
• 1027226-32-9 4-(2,6-dimethyl-benzylcarbamoyl)-thiazolidine-3-carboxylic acid tert-butyl ester 
• 186538-17-0 (R)-N-(2,6-dimethylbenzyl)-1,3-thiazolidine-4-carboxamide 
• 74788-82-2 (2,6-dimethylphenyl)methanamine 

Relevant academic research and scientific papers

COMPOSITIONS FOR PROMOTING READTHROUGH OF PREMATURE TERMINATION CODONS, AND METHODS OF USING THE SAME

Disclosed are compounds of general formula (I) that promote readthrough of a premature termination codon (PTC) of an RNA molecule in a translation system, and their use, alone or in combination with other compounds, such as aminoglycoside, to treat diseases or disorders ameliorated by modulation of a premature termination codon (PTC) of an RNA molecule in a translation system. The disorder or disease may be Dystrophic epidermolysis bullosa, Batten disease, Duchenne muscular dystrophy, cancer, and spinal muscular atrophy. Ar-L-B (I)

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Synthesis and cross-coupling reactions of imidomethyltrifluoroborates with aryl chlorides

Potassium imidomethyltrifluoroborate salts were efficiently synthesized. Potassium phthalimidomethyltrifluoroborate was successfully used in Suzuki-Miyaura-like cross-coupling reactions with a variety of aryl chlorides.

Compounds for the treatment of metabolic disorders

Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

We designed and synthesized a new class of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy- 4-phenylbutyric acid], with a hydroxymethylcarbonyl (HMC) isostere as the active moiety. A systematic evaluation of structure - activity relationships for HIV protease inhibition, anti-HIV activities, and pharmacokinetic profiles has led to the delineation of a set of structural characteristics that appear to afford an orally available HIV protease inhibitor. Optimum structures, exemplified by 21f (JE-2147), incorporated 3-hydroxy-2- methylbenzoyl groups as the P2 ligand, (R)-5,5-dimethyl-1,3-thiazolidine-4- carbonyl (Dmt) residue at the P1' site, and 2-methylbenzylcarboxamide group as the P2' ligand. The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals.

Novel isoxazole and isoxazoline compounds with anticonvulsant activity process for their preparation and therapeutic composition containing them

The object of the invention are anticonvulsant heterocyclic compounds of general formula: STR1 in which R1 and R2 is each selected from C1 -C4 alkyl, phenyl, benzyl, trifluoromethyl or halogen, R3 is